VANCOUVER, British Columbia Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today…
Eleven abstracts accepted for poster presentation highlight company’s differentiated antibody drug conjugate, multispecific antibody, and clinical product candidatesManagement will host a conference call on April 18th at 6:30 pm Eastern Standard Time (EST)VANCOUVER, British Columbia (BUSINESS WIRE) Zymeworks Inc..
2022 was a year of transformation and change:reported $412.5 million in total revenue for the year ended December 31, 2022;reported net income of $124.3 million ($1.90 per fully diluted share) for 2022 compared to net loss of $211.8 million in 2021;reported $492.2 million in cash resources as of December 31, 2022, w.
VANCOUVER, British Columbia (BUSINESS WIRE) Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2022 financial results after market close on March 7th, 2023. Following t.
Results presented today at ASCO GI include first overall survival (OS) data for zanidatamab, overall confirmed objective response rate (cORR) of 79%, disease.